This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NanoString Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

NanoString Technologies wird ein Gewinn- und Umsatzwachstum von 36% bzw. 16.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 44.9% pro Jahr wachsen soll.

Wichtige Informationen

36.0%

Wachstumsrate der Gewinne

44.9%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	0%
Wachstumsrate der Einnahmen	16.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Nov 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:NSTG * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	240	-77	-35	-19	5
12/31/2024	201	-96	-56	-45	7
12/31/2023	177	-157	-125	-107	7
9/30/2023	162	-166	-136	-115	N/A
6/30/2023	144	-166	-157	-133	N/A
3/31/2023	132	-161	-159	-134	N/A
12/31/2022	127	-160	-152	-129	N/A
9/30/2022	135	-145	-139	-118	N/A
6/30/2022	143	-139	-126	-109	N/A
3/31/2022	145	-127	-104	-92	N/A
12/31/2021	145	-115	-99	-91	N/A
9/30/2021	139	-109	-90	-84	N/A
6/30/2021	134	-99	-82	-76	N/A
3/31/2021	122	-99	-89	-83	N/A
12/31/2020	117	-110	-89	-82	N/A
9/30/2020	118	-63	-103	-90	N/A
6/30/2020	117	-65	-103	-90	N/A
3/31/2020	124	-57	-101	-89	N/A
12/31/2019	126	-41	-97	-89	N/A
9/30/2019	119	-86	-88	-84	N/A
6/30/2019	117	-80	-79	-75	N/A
3/31/2019	111	-80	-68	-64	N/A
12/31/2018	107	-77	-59	-54	N/A
9/30/2018	112	-65	-55	-52	N/A
6/30/2018	110	-60	-54	-51	N/A
3/31/2018	120	-44	-57	-54	N/A
12/31/2017	115	-44	-56	-52	N/A
9/30/2017	105	-46	-51	-46	N/A
6/30/2017	102	-45	N/A	-39	N/A
3/31/2017	90	-51	N/A	-29	N/A
12/31/2016	86	-47	N/A	-6	N/A
9/30/2016	84	-44	N/A	-4	N/A
6/30/2016	75	-44	N/A	-8	N/A
3/31/2016	66	-45	N/A	-19	N/A
12/31/2015	63	-46	N/A	-43	N/A
9/30/2015	56	-49	N/A	-44	N/A
6/30/2015	53	-52	N/A	-49	N/A
3/31/2015	50	-54	N/A	-42	N/A
12/31/2014	48	-50	N/A	-38	N/A
9/30/2014	42	-46	N/A	-43	N/A
6/30/2014	38	-42	N/A	-38	N/A
3/31/2014	34	-36	N/A	-35	N/A
12/31/2013	31	-34	N/A	-31	N/A
9/30/2013	28	-33	N/A	-25	N/A
6/30/2013	25	-30	N/A	-22	N/A
3/31/2013	24	-29	N/A	-21	N/A
12/31/2012	23	-25	N/A	-15	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NSTG * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NSTG * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NSTG * wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NSTG *Die Einnahmen des Unternehmens (16.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (7.1% pro Jahr).

Hohe Wachstumseinnahmen: NSTG *Die Einnahmen des Unternehmens (16.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NSTG * in 3 Jahren voraussichtlich hoch sein wird

This company listing is no longer active

NanoString Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

NanoString Technologies, Inc. Provides Product and Service Revenue Guidance for the Fourth Quarter and Full Year 2022

Nanostring Technologies, Inc. Provides Revenue Guidance for 2022

Nanostring Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

Recent updates

NS Wind Down Co. Files Form 15

NS Wind Down Co., Inc. Emerged from Bankruptcy

First Amended Disclosure Statement Approved for NanoString Technologies, Inc.

NanoString Technologies, Inc. announced delayed 10-Q filing

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

The Nasdaq Stock Market to Delist the Common Stock of Nanostring Technologies

NanoString Technologies, Inc. announced delayed annual 10-K filing

Patient Square Capital, LP agreed to acquire Substantially all assets of global business operations from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $220 million.

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from NASDAQ Composite Index

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from S&P Global BMI Index

Motion for Joint Administration Approved for NanoString Technologies, Inc.

Motion for Joint Administration Filed by NanoString Technologies, Inc.

NanoString Technologies, Inc. Filed for Bankruptcy

Nanostring Launches the CosMx 6,000 Plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

NanoString Technologies, Inc. Releases the First Public Dataset of the Whole Transcriptome Obtained At True Single-Cell Resolution on the CosMx Spatial Molecular Imager

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

NanoString Technologies, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NanoString Technologies, Inc. Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

Nanostring Appoints Todd Garland as Chief Commercial Officer

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.84 loss in 2Q 2022)

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

Delaware District Court Permits NanoString Technologies, Inc.'s Counterclaims That 10x Genomics and Harvard Violated the Antitrust Laws

NanoString Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

10X Genomics, Inc. Files New Patent Litigation Against Nanostring Technologies, Inc. and Vizgen, Inc. in the European Unified Patent Court

10X Genomics Wins Permanent Injunction Against Nanostring's CosMX Products

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Independent Director recently bought Mex$2.2m worth of stock

Full year 2022 earnings released: US$3.44 loss per share (vs US$2.54 loss in FY 2021)

NanoString Technologies, Inc. to Report Q4, 2022 Results on Feb 28, 2023

NanoString Technologies, Inc. Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

NanoString Technologies, Inc. Provides Product and Service Revenue Guidance for the Fourth Quarter and Full Year 2022

CEO, President & Director recently bought Mex$9.8m worth of stock

NanoString Technologies, Inc Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

Third quarter 2022 earnings released: US$0.79 loss per share (vs US$0.69 loss in 3Q 2021)

Now 21% undervalued after recent price drop

NanoString Technologies, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Now 30% undervalued

Now 20% undervalued

Now 21% undervalued after recent price drop

Now 20% undervalued

Nanostring Technologies, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$0.60 loss in 2Q 2021)

NanoString Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

NanoString Unveils AtoMx Spatial Informatics Portal at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

Nanostring Technologies, Inc. Announces Plans to Commercially Unveil the Cosmx™ Spatial Molecular Imager

NanoString Technologies, Inc. Launches Integrated Informatics to Facilitate Spatial Biology Research Using Next Generation Sequencing

NanoString Technologies, Inc. Announces Resignation of Robert Hershberg from the Board

NanoString Technologies, Inc. Launches New nCounter Pro Analysis System

NanoString Technologies, Inc. Announces Release of a Fully Automated GeoMx RNA Protocol on BOND RX Research Staining Systems

NanoString Technologies, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Nanostring Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken